Literature DB >> 365134

Liver allograft. Its use in chronic active hepatitis with macronodular cirrhosis, hepatitis B surface antigen.

J L Corman, C W Putnam, S Iwatsuki, A G Redeker, K A Porter, R L Peters, G Schröter, T E Starzl.   

Abstract

A patient suffering from chronic active hepatitis with macronodular cirrhosis, positive for hepatitis B surface antigen (HBsAg), was treated with an orthotopic liver allograft. The HBs antigenemia, as measured with several precipitation tests and by complement fixation, became negative after transplantation and remained so for about 2 1/2 months. During the interval, very low titers of the antigen were detectable by radioimmunoassay. At about three months after transplantation, she had an attack of acute hepatitis, at which time HBsAg became detectable by all tests. She recovered, but progressive liver disease developed during the remaining 1 1/2 years of her life. She died of disseminated nocardiosis and candidiasis with deteriorating hepatic function. The homograft at autopsy showed no evidence of rejection, but was the site of chronic active liver disease, although of a different pathologic pattern than that affecting her native liver. The differences in histology may reflect the influence of chronic immunosuppression on the features of chronic active hepatitis.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 365134      PMCID: PMC2952473          DOI: 10.1001/archsurg.1979.01370250077016

Source DB:  PubMed          Journal:  Arch Surg        ISSN: 0004-0010


  5 in total

Review 1.  Australia antigen and hepatitis.

Authors:  B S Blumberg; A I Sutnick; W T London; I Millman
Journal:  N Engl J Med       Date:  1970-08-13       Impact factor: 91.245

2.  Detection of Australia antigen and antibody by means of radioimmunoassay techniques.

Authors:  J H Walsh; R Yalow; S A Berson
Journal:  J Infect Dis       Date:  1970-05       Impact factor: 5.226

3.  Nocardia infections in a general hospital.

Authors:  J S Goodman; M G Koenig
Journal:  Ann N Y Acad Sci       Date:  1970-10-30       Impact factor: 5.691

4.  Cyclophosphamide and whole organ transplantation in human beings.

Authors:  T E Starzl; C W Putnam; C G Halgrimson; G T Schroter; G Martineau; B Launois; J L Corman; I Penn; A S Booth; C G Groth; K A Porter
Journal:  Surg Gynecol Obstet       Date:  1971-12

5.  Immunosuppression, liver injury, and hepatitis in renal, hepatic, and cardiac homograft recipients: with particular reference to the Australia antigen.

Authors:  M Torisu; T Yokoyama; H Amemiya; P F Kohler; G Schroter; G Martineau; I Penn; W Palmer; C G Halgrimson; C W Putnam; T E Starzl
Journal:  Ann Surg       Date:  1971-10       Impact factor: 12.969

  5 in total
  15 in total

1.  Incidence and severity of acute allograft rejection in liver transplant recipients treated with alfa interferon.

Authors:  A Jain; A J Demetris; R Manez; A C Tsamanadas; D Van Thiel; J Rakela; T E Starzl; J J Fung
Journal:  Liver Transpl Surg       Date:  1998-05

2.  Evolution of hepatitis B virus liver disease after hepatic replacement. Practical and theoretical considerations.

Authors:  A J Demetris; S Todo; D H Van Thiel; J J Fung; Y Iwaki; G Sysyn; W Ming; J Trager; T E Starzl
Journal:  Am J Pathol       Date:  1990-09       Impact factor: 4.307

3.  Infections complicating orthotopic liver transplantation: a study emphasizing graft-related septicemia.

Authors:  G P Schröter; M Hoelscher; C W Putnam; K A Porter; J F Hansbrough; T E Starzl
Journal:  Arch Surg       Date:  1976-12

4.  Hepatic transplantation and biliary atresia: early experience in eight patients.

Authors:  N L Ascher; J S Najarian
Journal:  World J Surg       Date:  1984-02       Impact factor: 3.352

5.  Current status of hepatic transplantation.

Authors:  S Iwatsuki; B W Shaw; T E Starzl
Journal:  Semin Liver Dis       Date:  1983-08       Impact factor: 6.115

Review 6.  Evolution of liver transplantation.

Authors:  T E Starzl; S Iwatsuki; D H Van Thiel; J C Gartner; B J Zitelli; J J Malatack; R R Schade; B W Shaw; T R Hakala; J T Rosenthal; K A Porter
Journal:  Hepatology       Date:  1982 Sep-Oct       Impact factor: 17.425

7.  Orthotopic liver transplantation in ninety-three patients.

Authors:  T E Starzl; K A Porter; C W Putnam; G P Schroter; C G Halgrimson; R Weil; M Hoelscher; H A Reid
Journal:  Surg Gynecol Obstet       Date:  1976-04

8.  Recurrent hepatitis B in liver allograft recipients. Differentiation between viral hepatitis B and rejection.

Authors:  A J Demetris; R Jaffe; D G Sheahan; J Burnham; J Spero; S Iwatsuki; D H Van Theil; T E Starzl
Journal:  Am J Pathol       Date:  1986-10       Impact factor: 4.307

9.  Fifteen years of clinical liver transplantation.

Authors:  T E Starzl; L J Koep; C G Halgrimson; J Hood; G P Schroter; K A Porter; R Weil
Journal:  Gastroenterology       Date:  1979-08       Impact factor: 22.682

10.  Post-transplant recurrent hepatitis B viral liver disease. Viral-burden, steatoviral, and fibroviral hepatitis B.

Authors:  M J Phillips; R Cameron; M A Flowers; L M Blendis; P D Greig; I Wanless; M Sherman; R Superina; B Langer; G A Levy
Journal:  Am J Pathol       Date:  1992-06       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.